Recruitment Status

Recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

21991

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Thrombocytopenia, Neonatal Alloimmune
Interventions: Nipocalimab, Intravenous immunoglobulins (IVIG), Prednisone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 16
States / cities: Birmingham, Alabama • Sacramento, California • Aurora, Colorado + 13 more

Conditions: Breast Cancer
Interventions: Inavolisib, Ribociclib, Fulvestrant, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 11
States / cities: Anaheim, California • Palo Alto, California • Jacksonville, Florida + 8 more

Conditions: Degenerative Spine Disease
Interventions: FIBERGRAFT™ Aeridyan Matrix Bone Graft Substitute, Demineralized Bone Matrix; Device
Lead sponsor: DePuy Synthes Products, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Sacramento, California • Chicago, Illinois • Lexington, Kentucky + 2 more

Conditions: Generalized Anxiety Disorder
Interventions: ITI-1284 10 mg, ITI-1284 20 mg, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 25
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 21 more

Conditions: Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8
Interventions: Pembrolizumab, Tivozanib, Biospecimen Collection, MRI, Computed Tomography, Biopsy, Questionnaire Administration; Biological · Drug · Procedure + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,040 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 429
States / cities: Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 340 more

Conditions: Hemolytic Disease of the Fetus and Newborn
Interventions: Standard of Care; Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 5
States / cities: Indianapolis, Indiana • Rochester, New York • Cincinnati, Ohio + 2 more

Conditions: HIV -1 Infection
Interventions: Every 4-week long-acting injectable cabotegravir and rilpivirine; Drug
Lead sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: La Jolla, California • Los Angeles, California • Aurora, Colorado + 7 more

Conditions: Insomnia, Nightmares Associated With Trauma and Stress, Nightmares, PTSD - Post Traumatic Stress Disorder
Interventions: Cognitive Behavioral Therapy for Insomnia, Cognitive Behavioral Therapy for Insomnia and Nightmares, Sleep Education, Sleep Education enhanced with Nightmare Education; Behavioral
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Crohn Disease, Colitis, Ulcerative
Interventions: Tulisokibart, Placebo to tulisokibart; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: Not listed
Enrollment: 1,380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 12
States / cities: Bristol, Connecticut • Ypsilanti, Michigan • Liberty, Missouri + 8 more

Conditions: Major Depressive Disorder (MDD), Treatment Resistant Depression, Major Depression
Interventions: MagVenture TMS Therapy System with Localite Navigation System and actiCHamp EEG; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 22 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Interventions: Fezolinetant, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: New Haven, Connecticut • Columbus, Ohio

Conditions: Pain, Normal Physiology, Healthy Volunteers
Interventions: Instructions, Attention, Thermal Pain, Placebo instructions; Behavioral
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Recruiting clinical trials

Filter and sort this status page

Live official records

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

FIBERGRAFT Aeridyan Posterolateral Fusion Study

Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry

Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

Restorative Early Sleep Treatment After the Emergency Department

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

EEG-Guided Transcranial Magnetic Stimulation for Adults With Depression

FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

Neural and Psychological Mechanisms of Pain Perception